|Dr. James R. Hollingshead Ph.D.||Pres, CEO & Director||69.81k||N/A||1963|
|Mr. Wayde D. McMillan||Exec. VP,CFO & Treasurer||946.57k||N/A||1970|
|Mr. Charles Alpuche||Exec. VP & COO||1.03M||N/A||1960|
|Mr. John Wodick Kapples||Sr. VP & Gen. Counsel||783.36k||N/A||1960|
|Ms. Shacey Petrovic||Director & Advisor||1.72M||14.82M||1974|
|Mr. Bret Christensen||Exec. VP & Chief Commercial Officer||883.8k||766.05k||1971|
|Ms. Lauren Budden||VP, Chief Accounting Officer & Controller||N/A||N/A||N/A|
|Ms. Deborah R. Gordon CPA||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Michael Spears||Sr. VP of Regulatory Affairs & Compliance||N/A||N/A||1965|
|Angela Geryak Wiczek||Sr. Director of Corp. Communications||N/A||N/A||N/A|
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corporation’s ISS governance QualityScore as of 1 June 2022 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 6; Compensation: 3.